Sindromu Katastrofiku ta' Antifosfolipidi (CAPS / Sindrome ta' Asherson): Maltempata ta' Trombożi Mikrovaskulari Multi-Organi Fi żmien Ġimgħa u Terapija Tripla bi Plasmaferesi¶

Catastrophic Antiphospholipid Syndrome (CAPS, also eponymously known as Asherson's Syndrome after Dr. Ronald Asherson, who first described it in 1992) is the most fulminant, life-threatening variant of Antiphospholipid Syndrome (APS), striking less than 1 percent of APS patients (with nearly 50 percent of cases occurring as the very first clinical presentation in a patient who never knew they had APS). Whereas classic APS typically causes a single large-vessel venous or arterial clot (such as a single deep vein thrombosis, pulmonary embolism, or stroke) or recurrent pregnancy loss, CAPS is an explosive, complement-amplified "thrombotic storm" (Thrombotic Microangiopathy [TMA] + systemic inflammatory response syndrome [SIRS]) that simultaneously occludes the small microvessels of three or more organ systems within less than 7 days, most frequently the kidneys (73%: malignant hypertension, proteinuria, and acute renal failure), lungs (60%: ARDS, pulmonary embolism, and diffuse alveolar hemorrhage), brain (56%: stroke, seizures, cerebral venous thrombosis, and encephalopathy), heart (50%: myocardial micro-infarction and Libman-Sacks valve vegetations), skin (47%: livedo racemosa, painful digital ischemia, and cutaneous necrosis), and adrenal glands (bilateral adrenal hemorrhage/infarction causing refractory hypotensive shock). Because CAPS is driven by a "Two-Hit" mechanism, where preexisting high-titer antiphospholipid antibodies (Lupus Anticoagulant [LA], Anti-Cardiolipin [aCL] IgG/IgM, u Anti-Beta-2-Glycoprotein-I [aB2GPI] IgG/IgM) are ignited by an acute "Second Hit" trigger (bacterial or viral infection in 49%, surgical procedures or trauma in 17%, abrupt withdrawal or subtherapeutic INR of Warfarin, malignancy, pregnancy/puerperium, or oral contraceptive estrogen), delaying treatment carries an 80 to 90 percent mortality rate, whereas immediate ICU initiation of CAPS "Triple Therapy" cuts mortality in half. If a patient with known Lupus (SLE), Antiphospholipid Syndrome, or unexplained thrombocytopenia develops sudden multi-organ symptoms (shortness of breath, confusion, chest or flank pain, mottled purple skin, or dark/absent urine), call your local numri ta' emerġenza immediately. Also review our companion guides on adrenal crisis and Addison's disease emergency injection, eclampsia seizures, HELLP syndrome, and postpartum preeclampsia, u sepsis and septic shock.

Your immediate emergency department and ICU priority is to launch full empiric "CAPS Triple Therapy" simultaneously at the very first clinical suspicion of multi-organ microvascular thrombosis (WITHOUT waiting days for confirmatory antiphospholipid antibody titers or tissue biopsy): (1) Therapeutic Intravenous Unfractionated Heparin (UFH) (not only to halt fibrin clot propagation, but because heparin directly inhibits complement activation [C3/C5 convertase]), (2) High-Dose Intravenous Corticosteroids (Methylprednisolone 500 to 1,000 mg/day IV for 3 days, followed by 1 to 2 mg/kg/day) (to extinguish the NF-kappa-B endothelial cytokine storm), and (3) Immediate Daily Therapeutic Plasma Exchange (Plasmapheresis / TPE exchanging 1.0 to 1.5 plasma volumes against Fresh Frozen Plasma/Albumin) AND/OR High-Dose Intravenous Immunoglobulin (IVIG, 0.4 g/kg/day IV for 5 days), while treating the underlying infectious trigger with broad-spectrum antibiotics and deploying the anti-C5 terminal complement inhibitor Eculizumab (Soliris) or anti-CD20 Rituximab for refractory cases.

Agħmel dan issa¶

1. Call your local emergency number or trigger an immediate ICU / Hematology / Rheumatology Rapid Response if a patient develops simultaneous thrombosis or acute organ dysfunction in >= 2 to 3 organs within a week. Dial 911 fl-Istati Uniti u l-Kanada, 999 fir-Renju Unit, 112 madwar l-Unjoni Ewropea, 000 fl-Awstralja, jew ikkonsulta d-direttorju tagħna ta numri ta' emerġenza. Remember that 46 to 50 percent of CAPS patients have NO prior diagnosis of APS or Lupus (SLE) before walking into the emergency room.
2. Start Pillar 1 of CAPS Triple Therapy Immediately: Therapeutic Intravenous Unfractionated Heparin (UFH) (Even in the Presence of Moderate Thrombocytopenia or Diffuse Alveolar Hemorrhage).
3. Unfractionated heparin is the mandatory cornerstone of CAPS survival (reducing mortality from > 75% to about 30% in the International CAPS Registry) both via antithrombin-mediated anticoagulation and direct inhibition of classic and alternative complement pathways.
4. Critical Laboratory Monitoring Pearl (The Lupus Anticoagulant aPTT Trap): Because the patient's circulating Lupus Anticoagulant (LA) antibodies artificially prolong the phospholipid-dependent baseline aPTT (often to 60 to 100+ seconds before heparin is even started), monitoring IV unfractionated heparin with a standard aPTT will trick you into severely under-dosing heparin. Always monitor IV Unfractionated Heparin in CAPS using a chromogenic Anti-Factor Xa (Anti-Xa) assay (target 0.3 to 0.7 IU/mL), NEVER the standard aPTT.
5. Start Pillar 2 of CAPS Triple Therapy Immediately: Pulse Intravenous Methylprednisolone (500 to 1,000 mg IV Once Daily for 3 Consecutive Days, Followed by 1 to 2 mg/kg/day IV). Never give corticosteroids alone without anticoagulation in CAPS, but alongside IV Heparin and Plasmapheresis, high-dose IV Methylprednisolone shuts down Anti-Beta-2-Glycoprotein-I (aB2GPI) activation of endothelial NF-kappa-B u Tissue Factor expression and simultaneously covers acute bilateral adrenal hemorrhage/infarction (which complicates 13% to 26% of CAPS cases).
6. Start Pillar 3 of CAPS Triple Therapy Within Hours: Daily Therapeutic Plasma Exchange (Plasmapheresis / TPE) AND/OR High-Dose Intravenous Immunoglobulin (IVIG).
7. Therapeutic Plasma Exchange (TPE, First-Line especially when Schistocytes / Microangiopathic Hemolytic Anemia [MAHA] or Renal Failure are present): Exchange 1.0 to 1.5 plasma volumes daily for at least 3 to 5 days using Fresh Frozen Plasma (FFP) (or 50:50 FFP + 5% Albumin) to mechanically strip pathogenic aB2GPI u aCL autoantibodies, cytokines (IL-1, IL-6, TNF-alpha), and complement fragments while replenishing natural anticoagulants (Antithrombin, Protein C, Protein S, and ADAMTS13).
8. High-Dose IVIG (0.4 g/kg/day IV for 5 days jew 1.0 g/kg/day for 2 days): Administer either alone (if apheresis catheter placement or TPE is delayed) or immediately after each daily Plasma Exchange session (never infuse IVIG right *before* a TPE session, or the apheresis machine will wash your expensive IVIG straight into the waste bag).
9. Hunt Down and Aggressively Treat the "Second-Hit" Precipitating Trigger (Infection in 49% of Cases). Draw STAT peripheral and line blood cultures, urine cultures, and viral panels, and start empiric broad-spectrum intravenous antibiotics immediately if any fever or infectious source is suspected. Never abruptly stop anticoagulation before surgery in a known Triple-Positive APS patient (always bridge closely with IV UFH or therapeutic LMWH).
10. Deploy Terminal Complement Inhibition (IV Eculizumab 900 mg Weekly) or Rituximab Early in Refractory CAPS or Prominent TMA (Schistocytes + Severe Thrombocytopenia + Renal Failure). Experimental and clinical evidence proves that severe CAPS is driven by runaway Terminal Complement Complex (C5b-9 membrane attack complex) deposition on endothelial cells (often with underlying complement regulatory gene mutations). Giving IV Eculizumab (Soliris) halts intravascular hemolysis, thrombocytopenia, and renal microvascular thrombosis within 48 to 72 hours when standard Triple Therapy is not enough.

Decision tree: suspected Catastrophic Antiphospholipid Syndrome (CAPS / Asherson's Syndrome) and ICU Triple Therapy¶

flowchart TD
    Patient["Patient Presents With Rapidly Progressive Multi-Organ Dysfunction (>= 3 Organs Within < 7 Days):<br/>- Renal: Acute Kidney Injury, Malignant HTN, Proteinuria<br/>- Pulmonary: ARDS / Diffuse Alveolar Hemorrhage / PE<br/>- CNS: Encephalopathy, Stroke, Seizures, CVST<br/>- Cardiac: Elevated Troponin, Myocardial Microthrombi<br/>- Skin: Livedo Racemosa, Digital Gangrene, Skin Necrosis<br/>- Adrenal: Flank/Abdominal Pain + Refractory Hypotension"] --> StatWorkup["STAT Bedside & Lab Triage (Do NOT Delay Treatment for Antibody Results):<br/>1. Peripheral Smear (Schistocytes), LDH, Haptoglobin, Platelets, Coags, Fibrinogen<br/>2. Draw Lupus Anticoagulant (dRVVT/aPTT), Anti-Cardiolipin IgG/IgM, & Anti-Beta-2-Glycoprotein-I IgG/IgM (BEFORE Plasma Exchange)<br/>3. Draw Random Cortisol & ACTH (Check for Bilateral Adrenal Hemorrhage) + ADAMTS13 Activity (Rule Out TTP)"]

    StatWorkup --> TripleTherapy["LAUNCH EMPIRIC 'CAPS TRIPLE THERAPY' IMMEDIATELY IN THE ICU"]

    TripleTherapy --> Pillar1["PILLAR 1: Therapeutic IV Unfractionated Heparin (UFH)<br/>- Monitor Strictly With Chromogenic ANTI-FACTOR Xa Level (Target 0.3 to 0.7 IU/mL)<br/>- NEVER Monitor With Standard aPTT (Falsely Prolonged by Lupus Anticoagulant)"]

    TripleTherapy --> Pillar2["PILLAR 2: High-Dose IV Corticosteroids<br/>- IV Methylprednisolone 500 to 1,000 mg Daily for 3 Days, Then 1 to 2 mg/kg/day<br/>- Blocks NF-kappa-B Endothelial Storm & Treats Adrenal Crisis"]

    TripleTherapy --> Pillar3["PILLAR 3: Daily Therapeutic Plasma Exchange (TPE) +/- High-Dose IVIG<br/>- Exchange 1.0 to 1.5 Plasma Volumes Daily x 5+ Days Using Fresh Frozen Plasma (FFP)<br/>- Infuse IVIG (0.4 g/kg/day x 5 Days) AFTER Each TPE Session (Never Right Before TPE)"]

    Pillar1 --> TriggerAndRefractory{"Treat 'Second-Hit' Trigger (Empiric Broad-Spectrum Antibiotics if Any Infection) & Assess 24-to-48-Hour Response"}
    Pillar2 --> TriggerAndRefractory
    Pillar3 --> TriggerAndRefractory

    TriggerAndRefractory -->|"Refractory Thrombocytopenia, Ongoing MAHA Schistocytes, or Worsening Organ Failure"| AddEculizumab["ESCALATE IMMEDIATELY:<br/>1. IV Eculizumab (Anti-C5 Complement Inhibitor: 900 mg IV Weekly x 4, Then 1,200 mg) [Give Meningococcal Vaccine + Ciprofloxacin/Penicillin Prophylaxis]<br/>2. IV Rituximab (375 mg/m2 Weekly x 4) to Deplete B-Cell Autoantibody Production"]

Part 1: The "Two-Hit" Pathophysiology of Asherson's Syndrome and International Diagnostic Criteria¶

1. Why Quiet Antiphospholipid Antibodies Suddenly Explode Into a 7-Day Multi-Organ Storm¶

Many individuals walk around for years with circulating "Triple-Positive" antiphospholipid antibodies (Lupus Anticoagulant + Anti-Cardiolipin + Anti-Beta-2-Glycoprotein-I) without developing a blood clot ("The First Hit"). Why? Because under normal resting conditions, vascular endothelial cells hide negatively charged membrane phospholipids on their inner leaflet, and circulating Beta-2-Glycoprotein-I (B2GPI) floats in a closed circular conformation that conceals its antigenic binding domain (Domain I).

• The "Second Hit" Trigger (Infection, Surgery, Trauma, Pregnancy, or Warfarin Withdrawal):
• When an infection (Gram-negative sepsis, respiratory virus, urinary tract infection), surgical tissue trauma, or obstetrical complication damages or activates vascular endothelial cells, negatively charged phosphatidylserine flips to the outer cell surface.
• Circulating B2GPI binds to the damaged endothelium and uncoils into an open "J-shaped fishhook" conformation, exposing Domain I.
• Pathogenic Anti-Beta-2-Glycoprotein-I (aB2GPI) IgG dimers cross-link the open B2GPI molecules on endothelial cells, platelets, and monocytes via Toll-Like Receptor 4 (TLR4) and Annexin A2, activating NF-kappa-B u p38 MAPK.
• The Complement Amplification Loop (C3a / C5a / C5b-9): The bound aB2GPI immune complexes trigger massive activation of the Classical and Alternative Complement Pathways, generating anaphylatoxins C3a u C5a (which recruit neutrophils to extrude prothrombotic NETs) and punching C5b-9 Membrane Attack Complex pores into microvascular endothelial cells throughout the kidneys, lungs, brain, heart, and adrenal glands.

2. Official Preliminary Classification Criteria for Catastrophic APS (Asherson et al. International Consensus)¶

Clinicians classify a patient as having Definite CAPS (all 4 criteria) or Probable CAPS (3 of 4 criteria) based on: 1. Criterion 1 (>= 3 Organs, Systems, or Tissues): Clinical evidence of involvement of three or more organs, systems, and/or tissues (renal, pulmonary, cerebral, cardiac, cutaneous, hepatic, gastrointestinal/mesenteric, splenic, or adrenal). 2. Criterion 2 (<= 7 Days): Development of clinical manifestations simultaneously or in less than one week. 3. Criterion 3 (Histopathologic Microthrombosis): Confirmation by histopathology of small-vessel occlusion (thrombotic microangiopathy) in at least one organ or tissue (typically via skin punch biopsy of livedo/necrotic lesions or renal biopsy once stabilized). 4. Criterion 4 (Laboratory Antiphospholipid Antibodies): Presence of Lupus Anticoagulant (LA), Anti-Cardiolipin (aCL IgG/IgM at medium-to-high titer > 40 GPL/MPL jew > 99th percentile), and/or Anti-Beta-2-Glycoprotein-I (aB2GPI IgG/IgM).

• When to Diagnose "Probable CAPS" and Treat Immediately at the Bedside: Because performing a kidney biopsy in a critically ill, anticoagulated, thrombocytopenic ICU patient is dangerous and waiting 12 weeks for repeat antibody confirmation is impossible during an acute crisis, the International Consensus defines Probable CAPS whenever:
• Only 2 organs are involved (with Criteria 2, 3, and 4 met), OR
• All 4 criteria are met except histopathologic biopsy confirmation is missing (because the patient is too unstable/anticoagulated to biopsy), OR
• 3 organs develop thrombosis over 1 to 4 weeks despite anticoagulation.
• Clinical Rule: Treat Probable CAPS identically to Definite CAPS with immediate full Triple Therapy.

Part 2: Side-by-Side Differential Diagnosis of ICU Thrombotic Microangiopathies (CAPS vs. TTP vs. HUS/aHUS vs. HIT vs. Sepsis DIC)¶

When an ICU patient develops rapidly falling platelets, rising creatinine, neurological confusion, and hemolytic anemia with schistocytes (helmet cells) on the blood smear, distinguishing CAPS from Thrombotic Thrombocytopenic Purpura (TTP), Sindromu Emolitiku Uremiku Medjat mill-Komplement (aHUS), HIT, u DIC Settiku huma kritiċi:

Part 3: Deep-Dive Into the 6 Organ Emergencies of CAPS (Including Bilateral Adrenal Hemorrhage & Diffuse Alveolar Hemorrhage)¶

Meta jimmaniġġjaw pazjent CAPS fl-ICU, il-kliniċi jridu jeżaminaw b'mod attiv u jimmaniġġjaw sitt kriżijiet ta' organi li jiddeterminaw is-sopravivenza:

========================================================================
   THE 6 SIGNATURE MULTI-ORGAN THROMBOTIC CRISES OF CAPS (ASHERSON'S)
========================================================================

  1. RENAL TMA (73%):               2. PULMONARY CRISIS (60%):
     Renal interlobular/glomerular     ARDS, Pulmonary Embolism, AND
     capillary microthrombi ->         Capillaritis DIFFUSE ALVEOLAR
     Malignant HTN + Oliguric AKI.     HEMORRHAGE (DAH: Hemoptysis +
                                       Falling Hb + Ground-Glass CT).
  3. CEREBRAL / CNS (56%):             * CRITICAL PEARL: Even with DAH,
     Microvascular Encephalopathy,       continue carefully titrated IV
     Seizures, Ischemic Stroke, &        Heparin + Pulse Steroids + TPE.
     Cerebral Venous Sinus Clots.
                                    4. CARDIAC MICRO-INFARCTION (50%):
  5. CUTANEOUS ISCHEMIA (47%):         Intramyocardial microthrombi
     Branching Livedo Racemosa,        (cardiogenic shock with clean
     Splinter Hemorrhages, Digital     epicardial coronaries) + Sterile
     Cyanosis/Gangrene, Skin Ulcers.   Libman-Sacks Mitral/Aortic Valves.

  6. BILATERAL ADRENAL HEMORRHAGE / INFARCTION (13% to 26% - OFTEN MISSED.):
     * Why the Adrenal Glands? Each adrenal gland is fed by 3 arteries
       (50-60 arterioles) but drained by ONLY A SINGLE CENTRAL ADRENAL VEIN.
     * Thrombosis of that single central adrenal vein causes hemorrhagic
       venous infarction of both adrenal cortices -> Sudden Flank/Abdominal
       Pain, Hyponatremia, Hyperkalemia, & Catecholamine-Resistant Shock.
     * Lifesaving Fix: Immediate Stress-Dose IV Hydrocortisone (100 mg IV
       bolus, then 50 mg IV q6h) or Pulse IV Methylprednisolone.
========================================================================

1. Il-Flixkun Anatomiku tal-Vina Adrenali (Why CAPS Causes Acute Addisonian Adrenal Crisis)¶

Għaliex emorraġija/infart adrenali bilaterali hija kumplikazzjoni klassika kemm ta' CAPS kif ukoll ta' HIT? - Kull glandola adrenali umana għandha provvista arterjali rikka (superior, middle, and inferior suprarenal arteries branching into 50+ capillary plexus vessels), but all venous blood must exit through a single, solitary Central Adrenal Vein (creating a vascular "water-hammer" bottleneck rich in platelet-activating catecholamines). - When CAPS microthrombi occlude that single central adrenal vein bilaterally, venous pressure inside the adrenal cortex skyrockets until the glands rupture and hemorrhage internally (Waterhouse-Friderichsen-like hemorrhagic infarction). - Clinical Red Flags: If a patient with APS/CAPS develops new bilateral flank, back, or epigastric pain, unexplained fever, falling serum sodium (hyponatremia), rising potassium (hyperkalemia), and hypotension refractory to norepinephrine, order an immediate Abdominal CT (which shows enlarged, hyperdense edematous adrenal glands), draw a STAT random serum Cortisol and ACTH, and immediately administer 100 mg IV Hydrocortisone bolus segwit minn 50 mg IV kull 6 sigħat (or make sure the patient is already receiving Pulse IV Methylprednisolone).

2. The Pulmonary Paradox: Managing Diffuse Alveolar Hemorrhage (DAH) Ġewwa Maltempata Protrombotika¶

Sa 60 percent of CAPS patients develop acute respiratory failure from ARDS, pulmonary thromboembolism, or non-thrombotic pulmonary capillaritis causing Diffuse Alveolar Hemorrhage (DAH: hemoptysis, diffuse bilateral alveolar infiltrates on chest CT, and a 1.5 to 3.0 g/dL overnight drop in hemoglobin). - How Can a Clotting Disease Cause Lung Bleeding? In CAPS, aB2GPI antibodies and C5a trigger immune-complex pulmonary capillaritis (neutrophilic inflammation that necroses the alveolar capillary wall) combined with pulmonary venular microthrombosis that raises hydrostatic capillary back-pressure until red blood cells pour into the air sacs. - How to Manage DAH in CAPS: 1. Immediately escalate immunosuppression with Pulse IV Methylprednisolone (1,000 mg/day IV x 3 days) + Daily Therapeutic Plasma Exchange (TPE) + IV Cyclophosphamide or Rituximab. 2. Carefully Balance Anticoagulation: If alveolar bleeding is life-threatening and platelets/fibrinogen are critically low, hold IV unfractionated heparin briefly for a few hours while administering Pulse Steroids and Plasma Exchange, but resume low-dose/titrated IV Unfractionated Heparin as soon as active hemoptysis stabilizes, because withholding heparin for days in CAPS allows microvascular thrombosis to destroy the brain, heart, and kidneys.

Part 4: Step-by-Step ICU Triple Therapy Execution & Refractory Rescue (Eculizumab & Rituximab)¶

1. The Exact CAPS Triple Therapy Checklist (McMaster / EULAR / International CAPS Registry Guidelines)¶

2. Salvataġġ Bijoloġiku tat-Tieni Linja għal CAPS Refrattarji (Eculizumab u Rituximab)¶

If a CAPS patient continues to experience falling platelets, rising creatinine, new neurological deficits, or refractory microangiopathic hemolysis after 24 to 48 hours of Triple Therapy: 1. Terminal Complement Blockade (IV Eculizumab [Soliris] jew Ravulizumab [Ultomiris]): - Why It Works: Over 60 percent of patients with refractory CAPS harbor severe complement activation (and many carry heterozygous mutations in complement regulatory genes like CFH, CFI, or CD46 identical to atypical HUS). Eculizumab (a humanized monoclonal antibody against complement protein C5) blocks cleavage of C5 into C5a u C5b-9, arresting endothelial TMA destruction within 24 to 72 hours. - Dosing: 900 mg IV once weekly for 4 weeks, followed by 1,200 mg IV on Week 5 and every 2 weeks thereafter. - Mandatory Meningococcal Prophylaxis: Because blocking C5b-9 creates susceptibility to encapsulated Neisseria meningitidis, administer quadrivalent (MenACWY) and Serogroup B (MenB) meningococcal vaccines immediately AND start daily oral antibiotic prophylaxis (Ciprofloxacin 500 mg daily jew Penicillin V 500 mg twice daily) from Day 1 of Eculizumab (do not delay Eculizumab for 2 weeks waiting for vaccine immunity). 2. B-Cell Depletion (IV Rituximab): - Administer Rituximab (375 mg/m2 IV once weekly for 4 weeks, or 1,000 mg IV on Days 1 and 15) (infused after daily TPE) to eliminate CD20+ B-lymphocytes producing pathogenic antiphospholipid autoantibodies, particularly in CAPS patients with severe thrombocytopenia, diffuse alveolar hemorrhage, or cardiac/CNS involvement.

Regional emergency numbers and international CAPS registries¶

• United States and Canada: Dial 911 for any suspected multi-organ thrombosis or stroke/PE emergency. Follow the McMaster University Clinical Practice Guideline for the Diagnosis and Management of Catastrophic Antiphospholipid Syndrome (Blood Advances) and American College of Rheumatology (ACR) / ASH guidance.
• European Union and United Kingdom: Dial 112 across the EU or 999 in the UK. Follow the European Alliance of Associations for Rheumatology (EULAR) Recommendations for the Management of Antiphospholipid Syndrome in Adults (Tektonidou et al., Annals of the Rheumatic Diseases) u s-Soċjetà Brittanika għall-Ematoloġija (BSH) Linji gwida. Il-kliniċisti madwar id-dinja jistgħu jikkonsultaw u jirreġistraw każijiet mar- Reġistru Internazzjonali CAPS (ontocrf.costaisa.com/en/web/caps, ospitat mill-Forum Ewropew dwar Antikorpi Antifosfolipidi fl-Isptar Clínic f'Barċellona, ​​Spanja, immexxi minn Dr Ricard Cervera).
• L-Awstralja u New Zealand: Ċempel 000 fl-Awstralja jew 111 fi New Zealand. Segwi THANZ u Assoċjazzjoni Awstraljana tar-Rewmatoloġija (ARA) Protokolli tal-ICU għal Terapija Tripla u aċċess ta' emerġenza għal Eculizumab.

Mistoqsijiet frekwenti¶

How is Catastrophic Antiphospholipid Syndrome (CAPS) different from regular Antiphospholipid Syndrome (APS)?¶

In classic Antiphospholipid Syndrome (APS), patients typically experience a single isolated blood clot in a large vein or artery (such as a deep vein thrombosis in one leg, a pulmonary embolism, or a stroke) or recurrent pregnancy complications, with normal function in the rest of their organs. Catastrophic Antiphospholipid Syndrome (CAPS, or Asherson's Syndrome) affects less than 1 percent of APS patients and acts like a sudden, body-wide microvascular "thrombotic storm": instead of one large clot, tiny blood clots simultaneously plug the microscopic capillaries of three or more critical organs (usually the kidneys, lungs, brain, heart, skin, and adrenal glands) within less than 7 days, accompanied by severe systemic inflammation and a falling platelet count.

Għaliex it-tobba jridu jagħtu tliet trattamenti fl-istess ħin eżatt ("Triple Therapy") biex isalvaw pazjent bil-CAPS?¶

Dejta storika mir-Reġistru Internazzjonali CAPS (li tkopri aktar minn 500 pazjent madwar id-dinja) wriet li t-trattament ta’ CAPS b’thinners tad-demm waħedhom jew sterojdi waħedhom falla fil-maġġoranza tal-każijiet, minħabba li l-CAPS għandu tliet magni li jsaħħu lilhom infushom: (1) Fibrina runaway u tikkumplimenta tagħqid f’bastimenti żgħar, (2) Maltempata ħarxa ta’ vażi tad-demm u vapuri infjammatorji ħarxa. konċentrazzjonijiet ta’ awtoantikorpi antifosfolipidi li jiċċirkolaw. "Triple Therapy" tattakka t-tliet magni simultanjament: Intravenous Unfractionated Heparin twaqqaf il-propagazzjoni tal-embolu u jinibixxi l-komplement, High-Dose IV Methylprednisolone jagħlaq il-maltempata taċ-ċitokini endoteljali, u Daily Therapeutic Plasma Exchange (Plasmapheresis) u/jew IVIG, tneħħi fiżikament l-autoantibodies 7 minn fuq in-newtralizzazzjoni. għal bejn wieħed u ieħor 30 fil-mija.

Għaliex l-infermiera u t-tobba ma jistgħux jużaw it-test tad-demm standard aPTT biex jimmonitorjaw l-Eparina ġol-vini f'pazjent b'CAPS?¶

Pazjenti b'CAPS kważi dejjem ikollhom antikorp antifosfolipidi li jiċċirkola msejjaħ "Lupus Anticoagulant" (LA). Paradossalment, għalkemm Lupus Anticoagulant jikkawża tagħqid sever tad-demm ġewwa l-ġisem tal-bniedem, ġewwa tubu tat-test tal-laboratorju tal-ħġieġ jeħel mar-reaġenti fosfolipidi użati biex imexxu t-test tal-Ħin Parzjali ta' Tromboplastina (aPTT) attivat standard, u b'mod artifiċjali jagħmel l-aPTT tal-linja bażi tal-pazjent jidher fit-tul (per eżempju, 85 sekonda) qabel ma tingħata qatra waħda ta' heparina. Jekk kliniċista juża l-aPTT biex tittratta d-dripp tal-eparina, bi żball jaħseb li d-demm tal-pazjent huwa "diġà rqiq wisq" u jdawwar it-taqtir tal-eparina għal livelli sub-terapewtiċi waqt li l-pazjent jagħqad għall-mewt. Minflok, IV Heparin f'CAPS għandha dejjem tiġi mmonitorjata b'livell tad-demm ta' Anti-Factor Xa (Anti-Xa) kromoġeniku (immirat 0.3 sa 0.7 IU/mL), li mhux affettwat mill-Antikoagulant Lupus.

Għaliex CAPS spiss jikkawża Kriżi Adrenali f'daqqa u ta' theddida għall-ħajja (xokk Addisonjan)?¶

Kull waħda miż-żewġ glandoli adrenali tiegħek (li joqogħdu fuq il-kliewi u jipproduċu l-kortisol u l-aldosterone li jsostnu l-ħajja) tirċievi d-demm permezz ta 'għexieren ta' arterji żgħar, iżda tixxotta d-demm kollu tagħha minn ġo Vena Adrenali Ċentrali waħda waħda. Waqt maltempata trombotika CAPS, il-mikro-emboli faċilment ipplaggjaw dik il-vina adrenali waħda li tixxotta fuq iż-żewġ naħat. Bil-vina tal-ħruġ imblukkata, id-demm arterjali jmur lura ġewwa ż-żewġ glandoli adrenali sakemm jintefħu u jinqatgħu internament (emorraġija adrenali bilaterali u infart). Dan jimsaħ il-produzzjoni tal-kortisol tal-ġisem matul il-lejl, u jikkawża uġigħ qawwi fil-ġenb jew fl-istonku, sodju baxx, potassju għoli u pressjoni tad-demm baxxa fatali sakemm ma tiġix ikkurata immedjatament b'kortikosterojdi ġol-vini b'doża għolja (Methylprednisolone jew Hydrocortisone).

Għaliex għandhom pazjenti b'APS Triple-Pożittiv jew CAPS preċedenti qatt ma jinqalbu minn Warfarin għal pillola moderna ta' Antikoagulanti Orali Diretti (DOAC) bħal Rivaroxaban jew Apixaban?¶

Provi kliniċi randomised multipli (inklużi l-provi TRAPS u ASTRO-APS) twaqqfu kmieni wara li skoprew li pazjenti b'Sindromu ta' Antifosfolipidi "Triple-Pożittiv" (pożittiv għal Lupus Anticoagulant, Anti-Cardiolipin, u Anti-Beta-2-Glycoprotein-I) li ħadu Direct Oral Anticoagulants jew tali apagulanti sofrew (riDOx AC) Rata ta' puplesiji arterjali u attakki tal-qalb minn 4 darbiet sa 7 darbiet ogħla minn pazjenti li qed jieħdu Warfarin. L-imblukkar ta 'fattur ta' tagħqid wieħed biss (Fattur Xa jew Fattur IIa) b'DOAC ħafna drabi huwa insuffiċjenti biex iwaqqaf it-trombina massiva u jikkumplimenta ż-żieda mmexxija minn antikorpi antifosfolipidi triple-pożittivi, u l-qlib minn Warfarin għal DOAC huwa trigger dokumentat għal APS Katastrofiku akut.

Sorsi u gwida uffiċjali¶

• McMaster University / Linja Gwida ta' Prattika Klinika ASH (Legault K et al., Blood Advances): Linja ta' Gwida ta' Prattika Klinika McMaster RARE-Bestpractices għad-Djanjożi u l-Ġestjoni tas-Sindrome Katastrofiku ta' Antifosfolipidi (Terapia Tripla: Antikoagulazzjoni, Skambju Glukokortikojdi, u IV).
• European Alliance of Associations for Rheumatology (EULAR, Tektonidou MG et al., Annals of the Rheumatic Diseases): EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults (Contraindication of DOACs in Triple-Positive APS and CAPS Management).
• International Consensus Statement on Classification Criteria and Treatment Guidelines for Catastrophic Antiphospholipid Syndrome (Asherson RA, Cervera R, et al., Lupus / Journal of Rheumatology): Preliminary Classification Criteria for Definite and Probable CAPS and Analysis of 500+ Patients from the International CAPS Registry.
• British Society for Haematology (BSH, Arachchillage DRJ et al.): Guidelines on the Investigation and Management of Antiphospholipid Syndrome and Catastrophic APS.
• New England Journal of Medicine (NEJM) Review (Garcia D, Erkan D): Diagnosis and Management of the Antiphospholipid Syndrome and Complement Inhibition in CAPS.

Gwidi relatati¶

• Adrenal crisis and Addison's disease emergency injection
• Heparin-induced thrombocytopenia (HIT) and VITT: 50 percent platelet drop on Day 5 to 10 and Argatroban
• Eclampsia seizures, HELLP syndrome, postpartum preeclampsia, and magnesium triage
• Sepsis u xokk settiku
• Numri ta' emerġenza skond il-pajjiż